Amgen to build new assembly and final packaging facility in Ohio
Greenfield construction of the new facility is expected to start later this year
Amgen will spend $365 million to build a new assembly and final packaging manufacturing facility in New Albany, Ohio, the biotech has announced.
The investment — in land acquisition, building construction and manufacturing equipment — will create what the company says will be its most advanced assembly and final product packaging capabilities for medicines to be distributed in the US.
Upon completion of the 270,000-sq. ft facility, the company expects to create 400 new jobs, hiring technicians, engineers, quality assurance, quality control, administrative and management positions, with a projected annual payroll of approximately $40 million.
Amgen Executive Vice President of Operations, Esteban Santos, said the expansion, which includes some of the company's "most advanced digital automation technologies" reflects the "anticipated growth in demand for Amgen medicines".
The decision to build the facility in New Albany (approximately 15 miles northeast of Columbus) centered on the location's vibrant business environment, growing talent pool, favourable operating costs and its central location from a logistics perspective.
In addition to being built in accordance with Amgen's goal of achieving carbon neutrality by 2027, the facility also will support the company's participation as a founding member of OneTen, a coalition of many of companies that aims collectively to hire one million Black Americans into well-paying jobs during the next 10 years, with a specific focus on those without a 4-year college degree.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.